0LC7 fundamentals
An in-depth look to SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) operating, investing, and financing activities
0LC7 free cash flow for Q1 24 is -31.1 M USD. For 2023, 0LC7 free cash flow was -110.04 M USD and operating cash flow was -109.77 M USD.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM